Navigation Links
FASgen Diagnostic Tests Identify Ovarian Cancer Progression and Apoptosis
Date:3/26/2008

BALTIMORE, March 26 /PRNewswire/ -- FASgen Diagnostics, LLC is pleased to report that results of studies using the Company's FAS-detect(TM) IHC and FAS- detect(TM) ELISA research tests were the subject of an address to Society of Gynecologic Oncologists annual meeting last week in Tampa, Florida. The report, "Over-expression of Fatty Acid Synthase (FAS) in Recurrent Ovarian Serous Carcinomas and its Potential Diagnostic and Therapeutic Role in Chemoresistant Disease," presented the data from studies conducted at the Johns Hopkins Oncology Center in cooperation with the Norwegian Radium Hospital.

The FAS-detect(TM) IHC test was used in evaluating 321 samples of serous ovarian cancer. FAS expression correlated with high grade disease and was an independent prognostic indicator. Patients with high levels of FAS expression survived for 36.9 months compared to 60.4 months for low expressors. Furthermore, FAS levels were highest in recurrent tumors. This is similar to prior findings in prostate and breast cancer. The FAS-detect(TM) ELISA was used to measure FAS levels in ovarian cancer ascites in 117 advanced stage serous carcinomas and 58 non-malignant controls, producing median results of 46.3 ng/ml of FAS in the ovarian cancer samples and 1.3 ng/ml in the controls.

The report further identifies the apoptotic effect of several FASi compounds from FASgen, Inc., an affiliated company of FASgen Diagnostics, LLC, which makes FASi compounds intended for therapeutic use in treating cancer. The results for FASgen's C-93 demonstrated significant apoptosis in SKOV3 and A2780 cell lines, i.e., > 70% within 48 hours. Similar findings were obtained with Taxol and Carboplatin resistant cell lines indicating that FAS inhibitors produce significant apoptosis to overcome hypoxia-induced chemoresistance. These in vitro data confirm the extensive xenograft results in ovarian, lung and colon cancers previously announced by FASgen. FAS is thus a promising target for chemoresistant and recurrent ovarian cancer.

About FASgen Diagnostics, LLC and FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

FASgen Diagnostics, LLC, an affiliated company, is a diagnostic company producing research tests for measuring the over expression of FAS in cancer. FAS-detect(TM) IHC and FAS-detect(TM) ELISA are marketed for research purposes.

FASgen has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com


'/>"/>
SOURCE FASgen Diagnostics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FASgen Announces New Research Discoveries in Lung Cancer
2. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
3. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
4. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
5. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
6. Hypertension Diagnostics Announces Fiscal Year 2007 Results
7. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
8. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
9. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
10. Aloka to Unveil New ProSound Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy
11. New peritoneal dialysis diagnostic discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: